Approval · Notice of Compliance 37873 · 2026
JAMP RISPERIDONE: Notice of Compliance 37873
Issued July 10, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37873
- Date
- July 10, 2026
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Administrative: Change in product name. Change in product name.Update to Product Monograph (to align with CRP approved PM). Update to package labels. Update to Instructions for Use
- Canadian reference product
- RISPERDAL ORAL SOLUTION (Janssen Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JAMP RISPERIDONE | 02454319 | Dormant |
Medicinal ingredients
- RISPERIDONE TARTRATE 1 MG per ML